(Q37345935)

19 August 2017

1 reference

title

Therapeutic options in acute severe ulcerative colitis (English)

1 reference

19 August 2017

3

Jack Satsangi

1 reference

19 August 2017

Nicola C Hare

1

1 reference

19 August 2017

Ian Dr Arnott

series ordinal

2

1 reference

19 August 2017

publication date

1 June 2008

1 reference

Expert Review of Gastroenterology & Hepatology

19 August 2017

published in

1 reference

19 August 2017

volume

2

1 reference

19 August 2017

issue

3

1 reference

19 August 2017

page(s)

357-370

1 reference

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Cortisone in ulcerative colitis; final report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Further experience in the treatment of severe attacks of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Predicting outcome in severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Current concepts and controversies in surgery for IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

IIeal Pouch-Anal Anastomoses Complications and Function in 1005 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Small bowel obstruction after total or subtotal colectomy: a 10-year retrospective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Long-term outcome after ileal pouch-anal anastomosis: function and health-related quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Systematic review: the management of pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Ciclosporin use in acute ulcerative colitis: a long-term experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Systematic review: Infliximab therapy in ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Predictors of response to infliximab in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Toxicity of infliximab in the course of treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Treatment with biologic therapies and the risk of cancer in patients with IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Increased risk for demyelinating diseases in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Serious adverse events with infliximab: analysis of spontaneously reported adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Steroid-refractory graft-vs.-host disease: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Response of refractory colitis to intravenous or oral tacrolimus (FK506).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Leukocytapheresis therapy for steroid-naïve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Leukocytapheresis is effective in inducing but not in maintaining remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial man

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.357

21 January 2018

Identifiers

DOI

10.1586/17474124.2.3.357

1 reference

19 August 2017

1 reference